MORRIS PLAINS, N.J., May 12 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
(Nasdaq: IMMU), a leading biopharmaceutical company focused on developing
monoclonal antibodies, today announced that three presentations will be given
at the 41st Annual Meeting of the American Society of Clinical Oncology
(ASCO), scheduled for May 13 - 17, 2005, in Orlando, Florida. The schedule
and meeting places for the general poster session, together with the abstract
and poster numbers are listed below:
* "Evaluation of a MAb-PAM4-defined MUC1 immunoassay as a potentially new
diagnostic test for pancreatic cancer" [Abstract No. 4102, Poster No.
P12, Saturday, May 14, 2:00 p.m. - 6:00 p.m., General Poster Session
Level 2, Hall C]
* "CEA radioimmunotherapy with 131I-labetuzumab improves survival post
salvage resection of colorectal cancer metastases in the liver"
[Abstract No. 3627, Poster No. H9, Saturday, May 14,
2:00 p.m. - 6:00 p.m., General Poster Session Level 2, Hall C]
* "Pretargeted radioimmunotherapy significantly improves the treatment of
non-Hodgkin's lymphoma in a nude mouse model" [Abstract No. 2548; Poster
No. F14, Sunday, May 15, 8:00 a.m. - 12:00 p.m., General Poster Session
Level 2, Hall C]
"Immunomedics is pleased to present these papers at ASCO which is a
testament to our core strength of bringing new technologies and antibodies
from our laboratories, as well as our subsidiary, IBC Pharmaceuticals, Inc.,
to the clinic," said Cynthia L. Sullivan, President and Chief Executive
Officer. "Our primary focus is to prepare for the pivotal Phase III trials
with epratuzumab for the treatment of patients with moderate to severe lupus."
Immunomedics is a biopharmaceutical company focused on the development of
monoclonal, antibody-based products for the targeted treatment of cancer,
autoimmune and other serious diseases. We have developed a number of advanced
proprietary technologies that allow us to create humanized antibodies that can
be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics or toxins, in each case to create
highly targeted agents. Using these technologies, we have built a pipeline of
therapeutic product candidates that utilize several different mechanisms of
action. We believe that our portfolio of intellectual property, which
includes approximately 90 issued patents in the United States, and more than
250 other issued patents worldwide, protects our product candidates and
technologies.
This release, in addition to historical information, contains forward-
looking statements made pursuant to the Private Securities Litigation Reform
Act of 1995. Such statements, including statements regarding clinical trials,
out-licensing arrangements, and capital raising activities, involve
significant risks and uncertainties and actual results could differ materially
from those expressed or implied herein. Factors that could cause such
differences include, but are not limited to, risks associated with new product
development (including clinical trials outcome and regulatory
requirements/actions), competitive risks to marketed products and availability
of financing and other sources of capital, as well as the risks discussed in
the company's Annual Report on Form 10-K for the fiscal year ended June 30,
2004. The company is not under any obligation, and the company expressly
disclaims any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise.
Company Contact: Chau Cheng, Associate Director, Investor Relations &
Business Analysis, (973) 605-8200, extension 123. Visit the Company's web site
at http://www.immunomedics.com .
SOURCE Immunomedics, Inc.
 back to top
Related links:
http://www.immunomedics.com
Company News On-Call:
http://www.prnewswire.com/comp/113121.html
CONTACT:
Chau Cheng, Associate Director, Investor
Relations & Business Analysis, Immunomedics, Inc.,
+1-973-605-8200, ext. 123
|
